Ipilimumab

Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies[1].

Product Specifications

CAS Number

[477202-00-9]

Product Name Alternative

MDX-010; BMS-734016

UNSPSC

12352203

Target

CTLA-4

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Anti-CTLA-4_Neutralizing_Antibody.html

Purity

99.88

Solubility

H2O

Smiles

[Ipilimumab]

Molecular Weight

(145.38 kDa)

References & Citations

[1]Movva S, et al. The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management. Expert Opin Biol Ther. 2009 Feb;9 (2) :231-41.|[2]Mark J Selby, et al. Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology. PLoS One. 2016 Sep 9;11 (9) :e0161779.